Study Focus:

HiLo is a large, pragmatic, 45-month trial funded by the National Institutes of Diabetes and Digestive and Kidney Diseases. The study’s primary aim is to determine the effects of liberalizing the serum phosphate target (“Hi”) versus maintaining aggressive phosphate control (“Lo”) for end-stage renal disease patients receiving treatment with maintenance hemodialysis.

Study Population:
4,400 patients being treated with hemodialysis across more than 120 dialysis facilities operated by large, mid-sized and smaller dialysis organizations in the United States.